Atara Biotherapeutics Inc

Most Recent

• 

  .

  Company & Industry Overviews

  Understanding Atara Biotherapeutics’ Licensing and Collaboration Agreements

  In September 2014, Atara Biotherapeutics (ATRA) entered into an exclusive option agreement with Memorial Sloan Kettering Center (or MSK).

• 

  .

  Company & Industry Overviews

  A Deeper Look at Atara Biotherapeutics’ ATA129, ATA520, and ATA230

  In April 2017, Atara Biotherapeutics (ATRA) entered into an agreement with Merck (MRK) to evaluate ATA129 in combination with Merck’s Keytruda.

• 

  .

  Company & Industry Overviews

  Where Atara Biotherapeutics Stands This January: Analyst Ratings

  Atara Biotherapeutics (ATRA) is a company focused on developing novel T-cell immunotherapy treatments for patients with cancer and multiple sclerosis.

• 

  .

  Company & Industry Overviews

  Inside Atara Biotherapeutics’ Promising Product Pipeline

  Atara’s most advanced T-cell therapy in development is its ATA129, which is under development for the treatment of cancer patients with Epstein Barr virus.

• 

  .

  Fund Managers

  Analyzing The Baupost Group’s Holdings in 4Q14

  The Baupost Group generated $21.5 billion in returns over its history. The recent 13F filing revealed that its 4Q14 portfolio declined more to $5.09 billion.

• 

  .

  Fund Managers

  Baupost discloses stake in Paratek Pharmaceuticals

  Seth Klarman’s The Baupost Group added a 12.04% stake in Paratek Pharmaceuticals, Inc. (PRTK), according to a 13G filing in December.

• 

  .

  Fund Managers

  Forward Pharma: One of Baupost’s new positions

  Seth Klarman’s The Baupost Group added a 11.72% stake in Forward Pharma (FWP). A November 13G filing shows the fund owns 5,367,300 Forward Pharma shares.

• 

  .

  Fund Managers

  Baupost nearly doubles position in Cheniere Energy

  In its 13G filing in January, The Baupost Group upped its stake in Cheniere Energy (LNG), giving it 10.01% stake in LNG and nearly doubling its 3Q14 filing.